H

Hummingbird Bioscience

Develops precision biotherapeutics for cancer

Cell Line Development / Upstream Process Development Intern

Bioprocess & BiomanufacturingPosted on Nov 20
InternshipSingaporeNo salary listedIn-person

About the Job

Requirements

  • Currently enrolled in a Bachelor of Science or Engineering program.
  • Competency in suspension cell culture and aseptic techniques is preferred.
  • Competency in Microsoft Word, Excel, and PowerPoint.
  • A basic understanding of cell biology, biologics manufacturing, and process development.
  • Able to commit to a 20-week internship period.

Responsibilities

  • Perform aseptic handling in a biosafety cabinet.
  • Perform cell culture in shake flasks and handle bioreactors routinely.
  • Perform cell culture analysis using manual hemacytometer or automated cell-counting methods, and use metabolite analyzers routinely.
  • Perform chromatography purification, including affinity and multimodal chromatography, using ÄKTA systems.
  • Prepare cell culture media and purification buffers for various process development steps.
  • Record data accurately, legibly, and in a timely fashion.
  • Analyze and present information using Microsoft Word, Excel, and PowerPoint.
  • Support data analysis and technical documentation writing.

Desired Qualifications

  • Experience in aseptic techniques and biosafety cabinet work.
  • Experience in downstream purification techniques using an ÄKTA.

About the Company

Hummingbird Bioscience

Develops precision biotherapeutics for cancer

Hummingbird Bioscience develops precision biotherapeutics for cancer and autoimmune diseases using a data-driven Rational Antibody Discovery platform. The platform combines biology, data analysis, and technology to engineer next-generation therapies and target biologically validated but previously undruggable targets. It advances drugs through biomarker-driven clinical trials, using measurable biomarkers to assess treatment effectiveness and guide development. The company differentiates itself by applying a systems biology approach and multi-omics data to design antibodies and therapies with higher specificity, aiming to improve clinical outcomes in patients who do not respond to current treatments. Its goal is to bring effective, targeted treatments to market that address unmet medical needs in oncology and autoimmunity.

Company size
51-200
Company stage
Series C
Total funding
$163.1M
Headquarters
Singapore, Singapore
Founded
2015

Recently Posted Jobs

Explore more opportunities at Hummingbird Bioscience

See more jobs